Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Two Nicotine 2 mg Lozenge Formulations in Healthy Smokers
NCT03432273Phase 1Completed
- Sponsor
- Fertin Pharma
- Start
- Feb 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nicotine in nicotine dependence (2 arms), sponsored by Fertin Pharma. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve from time 0 to last measurable concentration. Started Feb 2018; status: completed.
02
Drugs
nicotine
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT03432273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03432273.